CONTEXT: Report of the keynote speaker address at HIMSS Accelerate Health event confirming the importance of RWD and stressing the importance of maintaining partnerships across the evidence spectrum.
IMPACT: Low
READ TIME: 1 min
Quality Level Mean [1 – 10]: 7
1. ““What we really want to be able to do is leverage many of those learnings that we garnered from this experience and really institutionalize those in the health system as we move forward, and how we reimagine clinical discovery, clinical development and even commercialization of drug therapies as much more of an ecosystem in our world today,” Christopher Boone, VP and global head of health economics and research outcomes at Abbvie, said yesterday at HIMSS’ Accelerate Health event.”
2. “As someone with an extensive background in clinical drug research and development, the expanding use of real-world data was top of mind for Boone’s keynote presentation.”
3. “This kind of data is any information gathered outside of the clinical trial setting and used across the life cycle of drug development.”
4. ““It’s just not optimal to conduct a formal randomized clinical trial for a population that is so small, so we rely heavily on the use of real-world data and real-world evidence to really understand the benefits and risks of all drug therapies,” he said.”
5. ““We have to find ways to better understand the needs of each other to better foster a world of trust and transparency in hopes that we can really build this learning healthcare system of more cross-sector partnerships that will enable better science, better clinical care.”